105 related articles for article (PubMed ID: 23234874)
1. Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma.
Cha SI; Choi KJ; Shin KM; Lim J; Yoo SS; Lee J; Lee SY; Kim CH; Park JY
Respiration; 2013; 85(2):175. PubMed ID: 23234874
[No Abstract] [Full Text] [Related]
2. Rituximab-induced subacute interstitial pneumonitis: a case report and review of literature.
Subramanian M; Manjunath R; Kilara N; Mohan Rao KN
J Cancer Res Ther; 2010; 6(3):344-6. PubMed ID: 21119272
[TBL] [Abstract][Full Text] [Related]
3. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Huang YC; Liu CJ; Liu CY; Pai JT; Hong YC; Teng HW; Hsiao LT; Chao TC; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Yu YB; Tzeng CH
Ann Hematol; 2011 Oct; 90(10):1145-51. PubMed ID: 21647583
[TBL] [Abstract][Full Text] [Related]
4. Rituximab-induced interstitial lung disease: case report and literature review.
Zayen A; Rais H; Rifi H; Ouarda M; Afrit M; Cherif A; Mezline A
Pharmacology; 2011; 87(5-6):318-20. PubMed ID: 21613805
[TBL] [Abstract][Full Text] [Related]
5. Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma.
Rashidi A; Oak E; Bartlett NL
Blood; 2015 May; 125(21):3354-5. PubMed ID: 25999445
[No Abstract] [Full Text] [Related]
6. Rituximab and lung disease.
O'Connor MB; Phelan MJ
Ir Med J; 2012 Oct; 105(9):314. PubMed ID: 23240291
[No Abstract] [Full Text] [Related]
7. [Subcutaneous Rituximab is effective and safe].
Häckel A
Med Monatsschr Pharm; 2014 Jan; 37(1):39-40. PubMed ID: 24490439
[No Abstract] [Full Text] [Related]
8. [Rituximab-induced interstitial lung disease].
Fernández Casares M; Espósito G; González A; Segovia J; Galperín Mde L; Del Valle E
Medicina (B Aires); 2013; 73(4):343-5. PubMed ID: 23924535
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
10. [Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
Dreyling M
Dtsch Med Wochenschr; 2011 Apr; 136(14):687-90. PubMed ID: 21448827
[No Abstract] [Full Text] [Related]
11. Interstitial pneumonitis related to rituximab therapy.
Burton C; Kaczmarski R; Jan-Mohamed R
N Engl J Med; 2003 Jun; 348(26):2690-1; discussion 2690-1. PubMed ID: 12826649
[No Abstract] [Full Text] [Related]
12. Rituximab-related cryptogenic organizing pneumonia and late onset neutropenia in a patient with non-Hodgkin lymphoma: report of two rare complications and review of the literature.
Urun Y; Dincol D; Kumbasar OO
J BUON; 2012; 17(3):602-3. PubMed ID: 23033310
[No Abstract] [Full Text] [Related]
13. [Interstitial pneumonitis related to rituximab therapy in primary macroglobulinemia: a case report and literatures review].
Bai X; Yang R; Sun X; Qian J; Zhu H; Cui Q; Wang C; Liu Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):1022-3. PubMed ID: 25417884
[No Abstract] [Full Text] [Related]
14. Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature.
Wu Y; Jia Y; Xu J; Shuai X; Wu Y
J Clin Pharm Ther; 2013 Jun; 38(3):249-53. PubMed ID: 23506410
[TBL] [Abstract][Full Text] [Related]
15. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
Dawson K
J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
[TBL] [Abstract][Full Text] [Related]
16. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma.
Liu X; Hong XN; Gu YJ; Wang BY; Luo ZG; Cao J
Leuk Lymphoma; 2008 Sep; 49(9):1778-83. PubMed ID: 18798110
[TBL] [Abstract][Full Text] [Related]
17. Predictors of acute adverse events from rapid rituximab infusion.
Lang DS; Keefe DM; Schultz T; Pearson A
Support Care Cancer; 2013 Aug; 21(8):2315-20. PubMed ID: 23525938
[TBL] [Abstract][Full Text] [Related]
18. No studies have shown improved overall survival with maintenance therapy.
Ujjani C
Clin Adv Hematol Oncol; 2014 Aug; 12(8):541, 544-6. PubMed ID: 25356580
[No Abstract] [Full Text] [Related]
19. Severe anemia during rituximab maintenance therapy for follicular lymphoma.
Liapis K; Harhalakis N; Stefanou G; Apostolidis J
J Clin Oncol; 2012 Mar; 30(8):e95-6. PubMed ID: 22231048
[No Abstract] [Full Text] [Related]
20. [Subcutaneous administration of MabThera for therapy of non-Hodgkin lymphomas frees patients and medical personnel].
Pflege Z; 2013 Apr; 66(4):253. PubMed ID: 23634557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
